Journal News

Does a protein hold the key to Alzheimer’s?

Jay Thakkar
Dec. 10, 2024

Alzheimer’s disease, or AD, is the best-known neurodegenerative disorder affecting cognitive functioning and accounts for 60% to 80% of dementia cases. Understanding the progression of AD is relevant for its treatment, and multiple hypotheses exist to explain how the disease progresses.

One of these is the tau hypothesis; tau is a protein that stabilizes microtubules, an important component in neurons. Misfolding of tau leads to its aggregation in cells. This accumulation of tau starts spreading throughout the brain of AD patients by moving from cell to cell.

In a recent study published in the Journal of Biological Chemistry, Joanna Cooper at the University of Maryland School of Medicine, Aurelien Lathuiliere at Massachusetts General Hospital and a team of researchers focused on a receptor called Sortilin-related receptor 1, or SORL1, that is involved in tau accumulation inside the cells.

“SORL1 has been associated with Alzheimer’s disease in a sense that mutations have been found that may be causative, but there is no consensus as to how that is working,” Cooper said. “Most research previously has focused on its role with amyloid beta, which is the other main player in Alzheimer’s disease.”

Prior research showed that lower levels of SORL1 increase the generation of a polypeptide called amyloid beta, the main component of amyloid plaque found in AD patients. This new research indicates SORL1 increases tau seeding, highlighting a contradiction in the role of SORL1 in AD progression.

“I think it’s a new line of research with the potential to have translational implications for patients,” Lathuiliere said.

With amyloid beta, loss of function of SORL1 is problematic, whereas in the context of tau there might also be a gain of toxic function, Cooper explained. “That adds a whole dichotomy into thinking about what SORL1 does,” she said.

Researchers need to do more work in the lab to determine if SORL1 is a therapeutically relevant target for AD patients.

“It was really easy to identify that it acts as a direct binding partner to tau,” Cooper said. That simple experiment quickly gave conclusive results.

 “It was a lot more challenging to dig into what can SORL1 do and try to understand something that gives us insight it’s actual physiological function.”

The team used surface plasmon resonance to detect the binding affinity of SORL1 with tau. They conducted immunofluorescence staining and Förster resonance energy transfer assays to understand where tau was positioned among cells and to understand the implication of specific SORL1 mutations in AD patients.

Even if SORL1 isn’t targeted directly for therapeutics, this finding “provides context for the machinery that is helping to traffic tau and opens up a lot more understanding about how that process happens,” Cooper said.

Overall, tau seeding causes AD to progress. Understanding where tau is within and among cells and the receptors responsible for cellular uptake and transport will help researchers explore avenues for treating AD.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Jay Thakkar

Jay Thakkar is a researcher, who specializes in computer-aided drug design and discovery. He earned a bachelor's degree in chemical engineering from the Dwarkadas J. Sanghvi College of Engineering in Mumbai, India, and a master's degree in chemistry from the Stevens Institute of Technology in Hoboken, New Jersey, where he studied drug discovery. His hobbies include reading, driving on open roads and walking in the park.
 

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

AI-designed biomarker improves malaria diagnostics
Journal News

AI-designed biomarker improves malaria diagnostics

Oct. 8, 2025

Researchers from the University of Melbourne engineered Plasmodium vivax diagnostic protein with enhanced yield and stability while preserving antibody-binding, paving the way for more reliable malaria testing.

Matrix metalloproteinase inhibitor reduces cancer invasion
Journal News

Matrix metalloproteinase inhibitor reduces cancer invasion

Oct. 8, 2025

Scientists at the Mayo Clinic engineered a TIMP-1 protein variant that selectively inhibits MMP-9 and reduces invasion of triple-negative breast cancer cells, offering a promising tool for targeted cancer research.

Antibiotic sensor directly binds drug in resistant bacteria
Journal News

Antibiotic sensor directly binds drug in resistant bacteria

Oct. 8, 2025

Researchers at Drexel University uncover how the vancomycin-resistant bacterial sensor binds to the antibiotic, offering insights to guide inhibitor design that restores antibiotic effectiveness against hospital-acquired infections.

ApoA1 reduce atherosclerotic plaques via cell death pathway
Journal News

ApoA1 reduce atherosclerotic plaques via cell death pathway

Oct. 1, 2025

Researchers show that ApoA1, a key HDL protein, helps reduce plaque and necrotic core formation in atherosclerosis by modulating Bim-driven macrophage death. The findings reveal new insights into how ApoA1 protects against heart disease.

Omega-3 lowers inflammation, blood pressure in obese adults
Journal News

Omega-3 lowers inflammation, blood pressure in obese adults

Oct. 1, 2025

A randomized study shows omega-3 supplements reduce proinflammatory chemokines and lower blood pressure in obese adults, furthering the understanding of how to modulate cardiovascular disease risk.

AI unlocks the hidden grammar of gene regulation
Feature

AI unlocks the hidden grammar of gene regulation

Sept. 30, 2025

Using fruit flies and artificial intelligence, Julia Zeitlinger’s lab is decoding genome patterns — revealing how transcription factors and nucleosomes control gene expression, pushing biology toward faster, more precise discoveries.